What to Ask About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Inquiry

If you or a loved one is experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about the connection to gastroparesis. The long-standing tradition of medical communication has focused on drug benefits, but evolving evidence now highlights the importance of discussing delayed gastric emptying as a potential adverse effect. This page outlines key questions to discuss with your healthcare provider.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for weight loss. Among its known adverse effects, gastrointestinal complications are prominent. Clinical trial data indicate that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% for the 0.5 mg dose and 36.4% for the 1 mg dose, compared to 15.3% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These reactions, including nausea, vomiting, and diarrhea, were most common during dose escalation, and discontinuation rates due to gastrointestinal issues were higher for Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) than for placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

The Link Between Ozempic and Gastroparesis

Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests. The pharmacological mechanism of Ozempic—slowing gastric motility as part of its glucose-lowering effect—provides a plausible mechanistic pathway linking the drug to gastroparesis. GLP-1 receptor agonists like semaglutide delay gastric emptying, which can exacerbate or unmask underlying gastroparesis. Postmarketing reports have raised concerns about pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, due to retained gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for significant gastric retention, a hallmark of gastroparesis.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. While the prescribing information lists gastrointestinal adverse reactions, it does not explicitly warn of gastroparesis as a distinct adverse effect. The label notes rare postmarketing reports of pulmonary aspiration related to retained gastric contents but does not directly address gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This gap may affect patients who develop gastroparesis symptoms and seek legal recourse, as they could argue that the manufacturer failed to provide adequate warnings about this specific risk.

Statute of Limitations for Ozempic Claims in Washington

For affected patients in Washington, attorney-related considerations include the statute of limitations for product liability claims. In Washington, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or reasonably should have been discovered. For wrongful death claims, the limit is also three years from the date of death. Patients who developed gastroparesis after using Ozempic should consult an attorney promptly to assess their case, as delays could bar recovery. The timeline between exposure and documented harm is crucial: gastroparesis may develop weeks to months after starting Ozempic, and symptoms can persist or worsen over time. Documenting the onset of symptoms, medical diagnoses, and the link to Ozempic use is essential for legal claims.

Conclusion: Evidence-Based Evaluation and Next Steps

In summary, Ozempic is associated with a range of gastrointestinal adverse reactions, including those that could mimic or cause gastroparesis. The mechanistic link through delayed gastric emptying is supported by the drug's pharmacology and postmarketing reports of retained gastric contents. However, the prescribing information does not explicitly warn of gastroparesis, which may be a point of contention in legal claims. Patients in Washington should be aware of the three-year statute of limitations and seek legal advice to preserve their rights. Evidence-based medical and legal evaluation is necessary to determine causation and liability. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or reasonably should have been discovered. For wrongful death claims, the limit is also three years from the date of death. It is important to consult an attorney promptly to avoid missing the deadline.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying, which can exacerbate or unmask gastroparesis. While the prescribing information lists gastrointestinal adverse reactions, it does not explicitly warn of gastroparesis. Postmarketing reports have raised concerns about retained gastric contents leading to pulmonary aspiration, highlighting the potential for significant gastric retention.

What evidence supports the link between Ozempic and gastroparesis?

Clinical trial data show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The drug's mechanism of delaying gastric emptying provides a plausible pathway. Postmarketing reports of pulmonary aspiration due to retained gastric contents further support the link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.